secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950170-24-033476
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reports Q4 net loss $29.5M, extends cash runway into 2H 2026; IND cleared for ADI-001 in lupus nephritis
--------------------------------------------------------------------------------

- Net loss $29.5M ($0.69/share) in Q4 2023 vs $29.9M ($0.72/share) in Q4 2022; full-year net loss $142.7M ($3.31/share) vs $69.8M ($1.70/share).
- Cash and equivalents $159.7M at Dec 31, 2023; raised net $91.8M from public offering and $19.3M from ATM in Jan 2024, extending runway into 2H 2026.
- FDA cleared IND for ADI-001 in lupus nephritis in Dec 2023; Phase 1 trial initiation expected in Q2 2024 with preliminary data in Q4 2024/Q1 2025.
- On track to file IND for ADI-270 in renal cell carcinoma in Q2 2024; Phase 1 clinical data expected in first half of 2025.
- Appointed Benjamin Hsu, M.D., Ph.D., as VP Clinical Development - Autoimmune, to lead autoimmune cell therapy programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/0000950170-24-033476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024033476/acet-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer